Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma

Completed · Phase 2

Conditions studied: Sarcoma

In brief

RATIONALE: Drugs used in chemotherapy such as soblidotin use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of soblidotin in treating patients who have advanced or metastatic soft tissue sarcoma.

Key facts

Study ID

NCT00064220

Run by

Daiichi Sankyo

Starts

2003-04-01

Expected to finish

2005-12-01

Last updated by the study team

2012-05-16

Who can join

Age: 15 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Alabama at Birmingham Comprehensive Cancer Center — Birmingham, Alabama, United States
• Indiana University Cancer Center — Indianapolis, Indiana, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Herbert Irving Comprehensive Cancer Center at Columbia University — New York, New York, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
• Veterans Affairs Medical Center - San Juan — San Juan, Puerto Rico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.